In 2025, 2% of all manuscripts sent for peer review were submitted using the guaranteed peer review benefit. These manuscripts were high quality, with an acceptance rate above 50%, showing that the ...
You do not currently have access to this content.
Cancer Res (2023) 83 (8_Supplement): LB321. Citation Format: Elizabeth Donohue Vo, Yang W. Zhang, Dave Rominger, Jillian M. Silva, Yang J. Zhang, Greg Lee, John ...
Abstract. Previously, we reported on a series of highly potent, selective, and non-covalent CDK7 inhibitors that demonstrated antiproliferative activity against triple-negative breast cancer (TNBC) ...
Annual Meeting 2025 AACR Journals Simultaneous Publications | American Association for Cancer Research AACR Annual Meeting 2025: AACR Journals’ Concurrent Publications These journal articles published ...
Cancer Immunol Res (2026) 14 (2_Supplement): A038.
Annual Meeting 2026 AACR Journals Simultaneous Publications | American Association for Cancer Research AACR Annual Meeting 2026: AACR Journals’ Simultaneous Publications These AACR journal articles ...
Cancer Res (2025) 85 (8_Supplement_1): 841. Measurement of plasma and tumor concentrations were completed using standard extraction techniques with quantitation by LC-MS/MS methods. Target modulation ...
Although significant progress has been made in systemic treatments, pancreatic cancer (PC) still remains the fourth leading cause of cancer-related deaths in the United States with an estimated 42,470 ...
1Department of Pathology, NYU Grossman School of Medicine, New York, New York.
1Department of Genetics, Yale University School of Medicine, New Haven, Connecticut.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results